About Regado

BOARD OF DIRECTORS

 
 

Dennis Podlesak, MBA
Chairman of the Board

Mr. Podlesak joined Domain as a Partner in 2007. Prior to Domain, Mr. Podlesak was a founder and the Chief Executive Officer of Cerexa Pharmaceuticals, which became a wholly-owned subsidiary of Forest Laboratories after Mr. Podlesak led the growth and sale of the company to Forest in January 2007. Prior to Cerexa, Mr. Podlesak was the Chief Executive Officer of Peninsula Pharmaceuticals, and after building the company, led the sale of Peninsula to Johnson & Johnson in June 2005.

Mr. Podlesak has over 20 years of strategic, operational and commercial experience within the pharmaceutical industry, and a track record of success growing companies and leading business development & licensing, financing and M&A initiatives. Prior to Peninsula, Mr. Podlesak served as Senior Vice President and Head of a North American Business Unit for Novartis AG and as a member of Novartis' Pharmaceutical Executive Committee and Global Leadership Team. Earlier in his career, Mr. Podlesak served as Vice President and Head of the CEC division of Allergan, Inc. and as member of Allergan's North American and Global Management Team. Mr. Podlesak spent the first ten years of his career with SmithKline Beecham (now GlaxoSmithKline plc) where he was promoted to eight positions of increasing responsibility during his tenure with the company.

Mr. Podlesak currently serves as Chairman of the Board of Corthera, Inc. and Regado Biosciences, and is a Board member of Avanir Pharmaceuticals, Dov Pharmaceuticals, and the non-profit organization Prevent Blindness.

Mr. Podlesak holds a B.A. in Business Administration and an M.B.A. from Pepperdine University.

 
 
 
 

Jesse Treu, Ph.D.

Dr. Treu has been a Partner of Domain since its inception 23 years ago.  He has been a director of over 30 early stage health care companies, 18 of which so far have become successful public companies.  Present board memberships include Aesthetic Sciences, Altea Therapeutics, BiPar Sciences, CoLucid, Regado Biosciences, SenoRx and Somaxon Pharmaceuticals.  Past board memberships include Biosite Diagnostics, Dianon Systems, DNX, GelTex Pharmaceuticals, Inspire Pharmaceuticals, Iomai, Lumisys, NPS Pharmaceuticals, Northstar Neuroscience, OraPharma, Sepracor, Trimeris and Viagene.  Dr. Treu has served as a Founder, President and Chairman of numerous venture stage companies. 

Prior to the formation of Domain, Dr. Treu had 12 years of experience in the health care industry.  Dr. Treu was V.P. of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures.  While at CW Ventures, he served as President and CEO of Microsonics, a pioneer in computer image processing for cardiology.  From 1977 through 1982, Dr. Treu led new product development and marketing planning for immunoassay and histopathology products at Technicon Corporation (now Siemens Medical Solutions Diagnostics).  Dr. Treu began his career with GE in 1973, initially as a research scientist developing thin film optical sensors for immunoassay testing and subsequently serving on the corporate staff with responsibility for technology assessment and strategic planning.

Dr. Treu holds a Bachelors of Science from Rensselaer Polytechnic Institute, and both a Masters and Doctor of Philosophy degree from Princeton University.

 
 
 
 

P. Sherrill Neff, J.D.

Mr. Neff is a founding partner of Quaker BioVentures.  Mr. Neff was previous Chairman of the Greater Philadelphia Venture Group, and previous President of the Pennsylvania Biotechnology Association.  He sits on the following boards of directors: Amicus Therapeutics, Biolex Therapeutics, Neuronetics, Optherion, Regado Biosciences, Resource Capital Corporation, University City Science Center, the Biotechnology Institute, and the Policy Board of WXPN at the University of Pennsylvania.

Prior to forming Quaker BioVentures, he was President, Chief Operating Officer, and a Director of Neose Technologies, Inc., a publicly traded life sciences company.  Previously, Mr. Neff was Senior Vice President, Corporate Development at U.S. Healthcare, Inc., a leading publicly traded health maintenance organization.  Mr. Neff was formerly a Managing Director in the investment banking division of Alex.Brown & Sons, and formerly an attorney at Morgan, Lewis & Bockius.

Mr. Neff is a graduate of Wesleyan University and the University of Michigan Law School.

 
 
 
 

Raphaël Wisniewski

Raphaël Wisniewski joined the Life Sciences team of Edmond de Rothschild Investment Partners in 2001. Raphaël Wisniewski worked in Healthcare Corporate Finance at Goldman Sachs starting at Salomon Smith Barney. He worked also in the Finance Department of General Healthcare in London, the private hospital group. Raphaël Wisniewski is a Director of Biospace Med, BT Pharma, Implanet, Novagali Pharma, OncoMethylome Sciences, Pamgene, Pangenetics and Regado Biosciences.

Raphaël is a graduate of the Ecole des Hautes Etudes Commerciales in Paris and holds a postgraduate diploma in Economics and Finance from the Institut d’Etudes Politiques (IEP), Paris.

 
 
 
 

Jeff Clark, MBA

Mr. Clark co-founded The Aurora Funds with Scott Albert in 1994.  He works primarily with Aurora's life sciences portfolio.  He pulls from his strategic planning and operational experience to help these companies create or refine business plans, build solid management teams, develop strategic partnerships and secure key customers.

Mr. Clark currently serves on the boards of several of Aurora's life science portfolio companies, including Aldagen, Argos Therapeutics, Hyperbranch Medical Technology, Metabolon, Regado Biosciences and Xsira Pharmaceuticals, assisting in the strategic direction of each.

Prior to forming Aurora, Mr. Clark spent thirteen years working in development and external affairs for Duke University (including Duke Comprehensive Cancer Center, Duke Medical Center and the School of Engineering).  Through Aurora, he hoped to close the gap between local universities and the venture capital community to facilitate the growth of life science companies.

Mr. Clark maintains strong ties to the RTP community, serving as past Chairman of the Board of North Carolina's Council for Entrepreneurial Development, the Board of Overseers of the Duke Comprehensive Cancer Center and the Board of Directors for TROSA and the Choral Society of Durham. Mr. Clark is also Founding Chair of NC EntrePAC and associated entities.

Mr. Clark holds a Bachelor of Science in Mechanical Engineering from Duke University and a MBA from the Fuqua School of Business at Duke University.

 
 
 
 

David J. Mazzo, Ph.D.
President and Chief Executive Officer

David J. Mazzo, Ph.D., joined Regado Biosciences in August 2008 as President and Chief Executive Officer.  Dr. Mazzo brings to Regado almost 25 years of experience in the pharmaceutical industry, most recently as President and CEO of Æterna Zentaris.  Dr. Mazzo also has served as President and CEO of Chugai Pharma USA, LLC, the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan, a member of the Roche Group, after holding senior management and executive positions in R&D at Schering-Plough, Hoechst Marion Roussel and Rhone-Poulenc Rorer.

Dr. Mazzo is a pharmaceutical executive and strategic leader with broad technical and managerial experience gained from working in a variety of multi-cultural and multi-lingual environments in the USA, Canada, Europe and Asia.  He is recognized for his strong strategic, scientific and regulatory expertise, upon which he has amassed a track record of approximately 25 years of successful global product development, registration and launch.  Dr. Mazzo has proven himself to be a change leader uniquely adept at driving working groups to new levels of performance and achievement.

Dr. Mazzo currently is Non-Executive Chairman of Psivida, Inc. and a Director of Avanir Pharmaceuticals.  He earned a Bachelor of Arts degree in the Honors Program (Interdisciplinary Humanities) and a Bachelor of Science degree in Chemistry from Villanova University.  In addition, Dr. Mazzo received his Master of Science degree in Chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst.  He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.